Key result
Mavacamten is linked to ~54-fold higher odds of decreased ejection fraction in safety reports.
Why the study?
In April 2025, US prescribing information for mavacamten allowed eligible stable patients to extend echocardiographic monitoring to every 6 months from week 12, motivating an examination of when systolic dysfunction-related events are reported relative to this schedule.
When do systolic dysfunction-related adverse events with mavacamten occur in FAERS relative to the extended 6-month echocardiographic monitoring schedule after week 12?
Observational (n=4,953)
When do systolic dysfunction-related adverse events with mavacamten occur in FAERS relative to the extended 6-month echocardiographic monitoring schedule after week 12?
FAERS pharmacovigilance data show that while reporting density of systolic dysfunction with mavacamten drops after the first 12 weeks, it remains steady throughout the rest of the first year (median onset 125 days) before declining in year 2, suggesting the 3-to-12-month window warrants careful evaluation following the April 2025 FDA label update allowing 6-month echo intervals.
Answers are grounded in this paper and cite their sources.
Mavacamten-related systolic dysfunction reports persist through month 12 despite early density decline; leaves open whether extended 6-month monitoring is adequate.
Aim: In April 2025, the US prescribing information for mavacamten allowed eligible stable patients to extend echocardiographic monitoring to every 6 months from week 12. We examined when systolic dysfunction-related events are reported relative to this schedule. Methods: We analyzed US Food and Drug Administration Adverse Event Reporting System (FAERS) reports from April 2022 to June 2026 listing mavacamten as primary or secondary suspect (n = 4953), using disproportionality analysis with restricted comparators. Time to onset was calculated after additional deduplication across case identifiers. Reporting density (events/30 days) was compared across monitoring intervals, restricted to reports with ≥12 months or ≥2 years of potential observation. Results: Ejection fraction decreased had the highest reporting odds ratio (ROR) among clinical terms with ≥10 reports (n = 181; ROR 53.64, 95% confidence interval [CI] 46.10–62.41) and remained elevated against a cardiomyopathy-spectrum comparator (ROR 3.23, 95% CI 2.23–4.67). Among 88 cases (median time to onset 125.0 days), reporting density fell from 13.21 events/30 days in the first 12 weeks to 3.79 from week 12 to month 9, without a clear difference from months 9–12 (rate ratio 1.14, 95% CI 0.48–3.01). With ≥2 years of potential observation, density was higher from week 12 to month 12 than in months 12–24 (rate ratio 3.68, 95% CI 1.38–11.40; 6 later events). Conclusion: Reporting density was highest in the first 12 weeks, with no clear further decline during the rest of the first year. This period warrants evaluation in eligible cohorts with documented echocardiography.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted an observational in Cardiomyopathy / Systolic dysfunction associated with mavacamten (n=4,953). Mavacamten vs. Restricted comparators including a cardiomyopathy-spectrum comparator; across monitoring intervals (first 12 weeks vs week 12 to month 9, months 9-12, and months 12-24) was evaluated on Ejection fraction decreased (disproportionality reporting odds ratio) and reporting density (events/30 days) across echocardiographic monitoring intervals (ROR 53.64, 95% CI 46.10-62.41). Mavacamten was associated with decreased ejection fraction, with reporting density falling from 13.21 to 3.79 events/30 days after week 12.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: